CVS HEALTH CorpCVS
CVS HEALTH Corp Financial Overview 2021–2025
CVS Health generated a massive $402.1 billion in revenue for FY2025, yet profitability collapsed under a $5.7 billion goodwill impairment and rising medical utilization costs. This stark divergence signals a conglomerate struggling to convert top-line scale into efficient margins as it pivots from legacy retail pharmacy to integrated value-based care. The company’s long-term growth trajectory remains aggressive, with annual revenue expanding from $292.1 billion in FY2021 to the $402.1 billion peak in FY2025, driven largely by premiums and services rather than front-store retail.
Despite the sales momentum, execution risks have compressed earnings power. Operating income plummeted 38.0% in FY2024 due to Medicare headwinds, a trend that persisted into FY2025 alongside $1.2 billion in legacy litigation charges. While the business remains a liquidity engine—generating $10.6 billion in operating cash flow during FY2025—the bottom line was hammered, with reported EPS sinking to $1.39. Consequently, the market priced these depressed earnings at a premium 57.1x multiple with shares trading at $79.36 to close FY2025, reflecting deep uncertainty over whether acquisitions like Oak Street Health can offset the drag from structural reimbursement pressures.
Recent Developments (Q3 and Q4 2025)
During Q3 2025, the company reported a $3.98 billion net loss despite total quarterly revenue rising 7.8% to $102.9 billion. While the Health Care Benefits segment improved profitability via favorable reserve adjustments, the Health Services unit saw margins compress even as revenue grew 11.6%. A major strategic development occurred in September 2025 when subsidiary Omnicare filed for Chapter 11 bankruptcy to manage litigation liabilities. Governance also tightened, with CEO J. David Joyner assuming the Board Chair role effective January 1, 2026.
Bulls point to robust demand, evidenced by an 11.9% annual revenue jump in the Pharmacy & Consumer Wellness segment. Bears argue that despite $8.5 billion in cash on hand to support the $0.665 quarterly dividend, execution risks persist, leaving shares trading at a demanding 54.5x P/E as of February 9, 2026.
What to watch: Omnicare bankruptcy restructuring outcomes; margin stabilization in Health Services.
Rev
$402.07B
FY2025
NI
$1.77B
FY2025
EPS
$1.40
FY2025
OCF
$10.64B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
CVS HEALTH Corp 8-K Report, Financial Results (Feb 10, 2026)
CVS Health Corporation filed an 8-K on February 10, 2026, to furnish a press release announcing its financial results for the three months and full year ended December 31, 2025. While the filing itself does not contain detailed financial figures, it directs investors to the press release (Exhibit 99.1) for this crucial information. The press release, therefore, is the primary source for understanding the company's recent performance and financial condition. Investors should carefully review the furnished press release to gain insights into key performance indicators, revenue growth, profitability, and any forward-looking statements or guidance provided by CVS Health. The 8-K filing serves as a formal notification and makes the press release publicly available, ensuring transparency regarding the company's financial reporting for the period ending December 31, 2025.
CVS HEALTH Corp 8-K Report, Regulation FD Disclosure (Dec 9, 2025)
CVS Health Corporation (CVS) filed an 8-K on December 8, 2025, to announce information presented at its 2025 Investor Day held on December 9, 2025. The key takeaway for investors is the company's issuance of an updated 2025 full-year financial outlook and the provision of its initial financial guidance for the 2026 full-year. This filing includes a press release (Exhibit 99.1) that details these financial projections and outlines the company's strategic priorities, offering investors a forward-looking perspective on CVS Health's performance and strategic direction. While the 8-K itself doesn't contain detailed financial statements, it directs investors to the furnished press release for critical updates. Investors should carefully review Exhibit 99.1 to understand the specific financial targets for both the remainder of 2025 and the upcoming 2026 fiscal year, as well as the strategic initiatives expected to drive these results. The company's disclosure aims to provide transparency and manage expectations regarding its financial trajectory and business plans.
CVS HEALTH Corp 8-K Report, Corporate Update (Nov 20, 2025)
CVS Health Corporation announced a significant leadership transition within its Board of Directors. Effective January 1, 2026, J. David Joyner, currently President and Chief Executive Officer, will assume the additional role of Chair of the Board. This move consolidates the CEO and Board Chair positions under Mr. Joyner, a common governance structure that can potentially streamline decision-making and strategic alignment. While Roger N. Farah will step down as Executive Chair, he will remain a member of the Board. Michael F. Mahoney will continue in his capacity as Lead Independent Director, which is crucial for maintaining independent oversight. Investors should monitor how this leadership change impacts the company's strategic direction and governance practices going forward.
CVS HEALTH Corp 8-K Report, Financial Results (Oct 29, 2025)
CVS Health Corporation (CVS) has filed a Current Report (8-K) on October 28, 2025, primarily to announce its financial results for the third quarter ended September 30, 2025. The company issued a press release on October 29, 2025, detailing these results, which is furnished as an exhibit to this filing. Investors should refer to this press release (Exhibit 99.1) for specific financial performance data, including revenues, earnings, and any segment-specific updates. While this 8-K filing itself does not contain the detailed financial figures, it serves as the official notification of their release. The furnished press release will be crucial for understanding CVS Health's operational and financial condition as of the reporting period. Investors are advised to review the press release for forward-looking statements, management's commentary on performance, and any updated guidance provided by the company. It is important to note that the information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act, meaning it does not carry the same legal implications as a formally filed report, but it is still a key disclosure for market participants.
CVS HEALTH Corp 8-K Report, Corporate Update (Sep 22, 2025)
CVS Health Corporation (CVS) announced on September 22, 2025, that its wholly owned indirect subsidiary, Omnicare, LLC, along with certain of its subsidiary entities, has voluntarily initiated Chapter 11 bankruptcy proceedings. This action is primarily driven by significant monetary damages imposed by the U.S. District Court for the Southern District of New York following recent litigation. Omnicare intends to leverage the Chapter 11 process not only to address these damages but also to confront broader financial challenges within the long-term care pharmacy industry and explore restructuring or sale options. Omnicare has secured a debtor-in-possession financing agreement to ensure continued operations during the court-supervised process. Combined with expected operational cash flow, this financing is intended to provide sufficient liquidity to meet all ongoing business obligations. While this is a significant event for Omnicare, CVS Health will be closely monitoring the outcomes of this restructuring process and its potential impact on the parent company.
View all 8-K filings →